司美格鲁肽联合二甲双胍对2型糖尿病伴腹型肥胖患者胰岛功能及糖代谢指标的影响  

Effects of smeglutide combined with metformin on islet function and glucose metabolism in patients with type 2 diabetes mellitus and abdominal obesity

作　　者：夏雪 施伟生[1] 郭敬[1] XIA Xue;SHI Weisheng;GUO Jing(Department of Endocrinology,Puyang People's Hospital,Puyang Henan 457000,China)

机构地区：[1]濮阳市人民医院内分泌科,河南濮阳457000

出　　处：《天津药学》2025年第1期28-31,共4页Tianjin Pharmacy

摘　　要：目的探讨司美格鲁肽联合二甲双胍对2型糖尿病(T2DM)伴腹型肥胖患者的影响。方法以随机数字表法将2022年8月至2024年8月在濮阳市人民医院就诊的98例T2DM伴腹型肥胖患者分为两组,每组49例。对照组采取二甲双胍治疗,观察组在此基础上联合司美格鲁肽治疗。治疗12周后,对比两组胰岛功能、糖代谢指标、体质量指数(BMI)、不良反应。结果对比治疗前,治疗后两组空腹胰岛素(FINS)、空腹C肽(FC-P)、胰岛素抵抗指数(HOMA-IR)、空腹血糖(FBG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、BMI均降低,且观察组低于对照组;两组胰岛素分泌指数(HOMA-β)增加,且观察组比对照组高,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论司美格鲁肽联合二甲双胍应用于T2DM伴腹型肥胖患者,有助于改善胰岛功能及糖代谢指标,管理体质量,且具有良好安全性。Objective To investigate the effect of smeglutide combined with metformin on patients with type 2 diabetes mellitus(T2DM)and abdominal obesity.Methods A total of 98 patients with T2DM and abdominal obesity treated in Puyang People's Hospital from August 2022 to August 2024 were randomly divided into two groups,with 49 cases in each group.The control group was treated with metformin,and the observation group was treated with smeglutide and metformin.After 12 weeks of treatment,islet function,glucose metabolism indexes,body mass index(BMI),and adverse reactions were compared between the two groups.Results Compared with before treatment,both groups showed a decrease in fasting insulin(FINS),fasting C-peptide(FC-P),insulin resistance index(HOMA-IR),fasting blood glucose(FBG),2-hour postprandial blood glucose(2hPG),glycated hemoglobin(HbA1c),and BMI after treatment,and data of the observation group were lower than those of the control group,After treatment,the insulin secretion index(HOMA-β)of the two groups were increased,and data of the observation group were higher than that of the control group,with statistically significant(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The application of smeglutide combined with metformin in patients with T2DM and abdominal obesity can help improve islet function and glucose metabolism indicators,manage body weight,and has good safety.

关 键 词：2型糖尿病 腹型肥胖 司美格鲁肽 二甲双胍 胰岛功能 糖代谢指标 

分 类 号：R587.1[医药卫生—内分泌]